Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination.
Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination.
复制标题
晚期小细胞未分化癌的化疗。
DOI：
--
复制
发表时间：
1978
影响因子：
39.2
通讯作者：
F. Hirsch
中科院分区：
文献类型：
--
作者：
H. Hansen;P. Dombernowsky;M. Hansen;F. Hirsch
一项对照临床试验对109例晚期小细胞间变性肺癌患者进行了三种药物和四种药物联合化疗的比较。长春新碱、1-(2-氯乙基)-3-环己基-1-亚硝脲(CCNU)、环磷酰胺和甲氨蝶呤联合用药在中位生存期(230天比176天)和有效时间(186天比112天)方面明显优于后三种药物单独用药(P<0.01)。客观有效率分别为78%和75%。在使用世界卫生组织分类的小细胞未分化癌的三种亚型的比较中，这些值没有明显的差异。
A controlled clinical trial compared three-drug and four-drug combination chemotherapy in 109 patients with advanced small-cell anaplastic carcinoma of the lung. The combination of vincristine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), cyclophosphamide, and methotrexate was significantly superior to the combination of the last three drugs alone with regard to median survival (230 versus 176 days) (P less than 0.01) and to duration of response (186 versus 112 days) (P less than 0.01). Objective response occurred in 78% and 75%, respectively. No significant difference in these values was observed in the comparison of the three subtypes of small-cell anaplastic carcinoma using the World Health Organization classification.